
-Mechanisms of cytokine receptor traffic and signaling :
Staerk J, Defour JP, Pecquet C, Leroy E, Antoine-Poirel H, Brett I, Itaya M, Smith SO, Vainchenker W, Constantinescu SN.
Orientation-specific signalling by thrombopoietin receptor dimers.
EMBO J. 2011 Sep 2. doi: 10.1038/emboj.2011.315.
Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN.
An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor.
Blood. 2006, 107:1864-71.
Royer Y, Staerk J, Costuleanu M, Courtoy PJ, Constantinescu SN.
Janus kinases affect thrombopoietin receptor cell surface localization and stability.
J Biol Chem. 2005, 280:27251-61.
Kubatzky KF, Liu W, Goldgraben K, Simmerling C, Smith SO, Constantinescu SN.
Structural requirements of the extracellular to transmembrane domain junction for erythropoietin receptor function.
J Biol Chem. 2005, 280:14844-54.
Seubert N, Royer Y, Staerk J, Kubatzky KF, Moucadel V, Krishnakumar S, Smith SO, Constantinescu SN.
Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer.
Mol Cell. 2003, 12:1239-50.
Constantinescu SN, Huang LJ, Nam H, Lodish HF.
The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif.
Mol Cell. 2001, 7:377-85.
-JAK2 V617F in human myeloproliferative neoplasms, JAK mutations in cancer :
Besancenot R, Chaligné R, Tonetti C, Pasquier F, Marty C, Lécluse Y, Vainchenker W, Constantinescu SN, Giraudier S.
A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation.
PLoS Biol. 2010 Sep 7;8(9). pii: e1000476.
Dusa A, Mouton C, Pecquet C, Herman M, Constantinescu SN.
JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors.
PLoS One. 2010 Jun 16;5(6):e11157.
Girardot M, Pecquet C, Boukour S, Knoops L, Ferrant A, Vainchenker W, Giraudier S, Constantinescu SN.
miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets.
Blood. 2010 Jul 22;116(3):437-45. Epub 2010 May 5.
Pecquet C, Staerk J, Chaligné R, Goss V, Lee KA, Zhang X, Rush J, Van Hees J, Poirel HA, Scheiff JM, Vainchenker W, Giraudier S, Polakiewicz RD, Constantinescu SN.
Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor.
Blood. 2010 Feb 4;115(5):1037-48. Epub 2009 Dec 8.
Dusa A, Staerk J, Elliott J, Pecquet C, Poirel HA, Johnston JA,
Constantinescu SN.
Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2.
J Biol Chem. 2008, 283:12941-8.
Constantinescu SN, Girardot M, Pecquet C.
Mining for JAK-STAT mutations in cancer.
Trends Biochem Sci. 2008, 33:122-31.
Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, Ariola C, Fodale V, Clappier E, Paoloni F, Martinelli S, Fragale A, Sanchez M, Tavolaro S, Messina M, Cazzaniga G, Camera A, Pizzolo G, Tornesello A, Vignetti M, Battistini A, Cavé H, Gelb BD, Renauld JC, Biondi A, Constantinescu SN, Foà R, Tartaglia M.
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.
J Exp Med. 2008, 205:751-8.
James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W.
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
Nature. 2005, 434:1144-8
Staerk J, Kallin A, Demoulin JB, Vainchenker W, Constantinescu SN.
JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor.
J Biol Chem. 2005, 280:41893-9.